
Topic
Patient Assistance
Manufacturer PAPs, copay cards, bridge programs, eligibility friction, and renewal workflows.

Pricing & Access· May 25, 2026 · 9 min read
By Ran Chen#PCSK9#Cardiovascular#Coverage Access

Pricing & Access· May 24, 2026 · 12 min read
IL-23 inhibitor access landscape: Skyrizi, Stelara, Tremfya, Omvoh, and Ilumya in 2026
By Ran Chen#Immunology#IL-23 Inhibitor#Coverage Access

Pricing & Access· May 24, 2026 · 12 min read
JAK inhibitor access landscape: Rinvoq, Xeljanz, Olumiant, Leqselvi, and Cibinqo in 2026
By Ran Chen#JAK Inhibitor#Immunology#Coverage Access

Pricing & Access· May 24, 2026 · 11 min read
SGLT2 inhibitor access landscape in 2026

Specialty· May 22, 2026 · 12 min read
Bridge programs after prior authorization denial: compliance boundaries

Pricing & Access· May 22, 2026 · 13 min read
Copay accumulator and maximizer monitoring for manufacturer support teams

Pricing & Access· May 22, 2026 · 10 min read
Dupixent vs Ebglyss: label, access, and payer coverage compared
By Ran Chen#Immunology#Prior Authorization#Payer Policy

Specialty· May 22, 2026 · 10 min read
REMS distribution design: when access controls become a specialty-pharmacy bottleneck

Pricing & Access· May 20, 2026 · 10 min read
Mounjaro vs Zepbound: label, access, and payer coverage compared
By Ran Chen#GLP-1#Coverage Access#Prior Authorization

Pricing & Access· May 19, 2026 · 15 min read
Humira coverage guide: formularies, biosimilars, prior authorization, assistance
By Ran Chen#Immunology#Prior Authorization#Payer Policy